Chemical Sciences / Medicinal Chemistry
/ Topic 5 of 5 · 5/5 Medicinal Chemistry Formula Sheet and Short Notes One-page CSIR NET revision: drug targets and inhibition constants, logP and QSAR, metabolism and pharmacokinetics formulas, and drug-class targets.
7 min read Updated 16 Nov 2026
Share
Copy link
Print · PDF
Save Share this topic
csirnetnotes.com/chemical-sciences/medicinal-chemistry/quick-revision
Copy link Ctrl C Pre-written message Medicinal Chemistry Formula Sheet and Short Notes — notes, formulas and practice, free. csirnetnotes.com/chemical-sciences/medicinal-chemistry/quick-revision
Every formula, target and trap from Drug Targets and Molecular Basis of Drug Action , Physicochemical Properties, SAR and QSAR , Drug Metabolism, Prodrugs and Pharmacokinetics and Major Drug Classes and Their Chemistry , on one page.
Constants used: \( R = 8.314 \) J K⁻¹ mol⁻¹; at 298.15 K, \( RT = 2.479 \) kJ mol⁻¹ and \( RT\ln 10 = 5.71 \) kJ mol⁻¹ (= 1.37 kcal mol⁻¹) per log unit.
Binding and inhibition $$\theta = \frac{[\mathrm{D}]}{K_d + [\mathrm{D}]}, \qquad \Delta G^\circ = RT\ln K_d, \qquad \mathrm{p}K_i = -\log K_i$$$$K_i = \frac{\mathrm{IC}_{50}}{1 + [\mathrm{S}]/K_M}\ (\text{enzyme}), \qquad K_i = \frac{\mathrm{IC}_{50}}{1 + [\mathrm{L}]/K_d}\ (\text{radioligand}), \qquad r - 1 = \frac{[\mathrm{B}]}{K_B}\ (\text{Schild})$$
One log unit of \( K_d \) = 5.7 kJ mol⁻¹ . \( K_d = 1 \) nM → −51.4 kJ mol⁻¹; 10 nM → −45.7 kJ mol⁻¹. At \( [\mathrm{S}] = K_M \), IC\(_{50} = 2K_i \). Schild slope 1 = simple competition; p\(A_2 = -\log K_B \); \( [\mathrm{B}] = 10^{-6} \) with \( r = 21 \) gives \( K_B = 5\times10^{-8} \), p\(A_2 = 7.3 \). Covalent inhibition: \( k_{\text{obs}} = k_{\text{inact}}[\mathrm{I}]/(K_I + [\mathrm{I}]) \); time-dependent, saturable, not reversed by dialysis. Inhibition type Lineweaver–Burk Apparent \( V_{\max} \) / \( K_M \) Competitive meet on \( 1/v \) axis \( V_{\max} \) same, \( K_M \) up Uncompetitive parallel both down Pure non-competitive meet on \( 1/[\mathrm{S}] \) axis \( V_{\max} \) down, \( K_M \) same
Receptor term Meaning Full / partial agonist maximal / submaximal plateau Inverse agonist below constitutive baseline Competitive antagonist parallel right shift, \( E_{\max} \) kept Irreversible antagonist \( E_{\max} \) depressed
⚠ Trap · Traps
IC\(_{50}\) quoted as a constant; \( K_d \) equated with EC\(_{50}\) when receptor reserve exists; potency confused with efficacy; a tight-binding reversible inhibitor called covalent; a partial agonist assumed to be merely weak.
Properties and drug-likeness $$\log D = \log P - \log\!\left(1 + 10^{\Delta}\right), \qquad \Delta = \mathrm{pH} - \mathrm{p}K_a\ (\text{acid}),\ \ \mathrm{p}K_a - \mathrm{pH}\ (\text{base})$$
\( \pi_X = \log P_{\mathrm{RX}} - \log P_{\mathrm{RH}} \); positive for alkyl, halogen, CF\(_3\); negative for OH, NH\(_2\), CONH\(_2\). Ionised fraction (acid) \( = 1/(1 + 10^{\mathrm{p}K_a - \mathrm{pH}}) \). Acid \( \mathrm{p}K_a \) 4.4 at pH 7.4: 99.9% ionised, \( \log D = \log P - 3.0 \). Only the neutral species crosses a membrane passively (pH–partition). Lipinski: mass ≤ 500, \( \log P \) ≤ 5, H-bond donors ≤ 5, acceptors ≤ 10 (≥2 violations = likely poor oral absorption).Veber: rotatable bonds ≤ 10, PSA ≤ 140 Å\(^2\) (lower still for CNS).At pH 7.4: COOH ionised, aliphatic amine protonated, amide and pyridine neutral. SAR, bioisosteres and QSAR $$\log\frac{1}{C} = -k_1(\log P)^2 + k_2\log P + k_3\sigma + k_4E_s + k_5, \qquad \log P_0 = \frac{k_2}{2k_1}$$
Tool Use Craig plot choose substituents spanning all four \( \pi \)–\( \sigma \) quadrants (avoid colinearity) Topliss tree stepwise, non-statistical substituent choice Free–Wilson additive group contributions, no physical parameters, no extrapolation CoMFA / 3D-QSAR aligned molecules, grid fields, PLS regression
Bioisostere Replaces Tetrazole, acylsulfonamide COOH F H (blocks metabolism, lowers amine \( pK_a \)) Pyridyl phenyl (lowers \( \log P \)) 1,2,4-Oxadiazole, trans-alkene amide
$$\mathrm{LE} \approx \frac{1.37\,\mathrm{pIC}_{50}}{N_{\text{heavy atoms}}}\ \text{kcal mol}^{-1}\text{ atom}^{-1}, \qquad \mathrm{LLE} = \mathrm{pIC}_{50} - \log P$$
Worked anchors: pIC\(_{50}\) 8 with 25 heavy atoms → LE 0.44; pIC\(_{50}\) 6 with 15 atoms → LE 0.55. \( \log(1/C) = -0.22(\log P)^2 + 1.32\log P + 1.60\sigma + 2.10 \) → \( \log P_0 = 3.00 \), best value 4.08 at \( \sigma = 0 \) (illustrative coefficients). ⚠ Trap · Traps
\( \log P \) used where \( \log D \) is needed, or the ionisation correction given the wrong sign; the parabolic term read as “more lipophilic is better”; the rule of five treated as a law; a QSAR with more descriptors than it can support, or extrapolated outside its training range.
Phase Chemistry I P450 oxidation (aliphatic and aromatic hydroxylation, N/O/S-dealkylation, N/S-oxidation, epoxidation, oxidative deamination); hydrolysis by esterases/amidases; reduction of nitro and azo groups II glucuronidation (UDPGA), sulfation (PAPS), glutathione conjugation (→ mercapturic acids), acetylation (acetyl-CoA), methylation (SAM), amino-acid conjugation
$$\mathrm{RH} + \mathrm{O_2} + \mathrm{NADPH} + \mathrm{H^+} \longrightarrow \mathrm{ROH} + \mathrm{H_2O} + \mathrm{NADP^+}$$
P450 is a haem-thiolate monooxygenase; CYP3A4 handles the largest share of drugs, CYP2D6 is notably polymorphic. Inhibition raises exposure quickly; induction lowers it over days (rifampicin, carbamazepine, St John’s wort are standard inducers).Bioactivation: arene oxides (NIH shift), quinone imines (paracetamol → NAPQI, captured by glutathione), acyl glucuronides, nitrenium ions. Blocking strategies: aromatic F, steric shielding, amide for ester, remove the catechol. Prodrug on, soft drug off. Enalapril (ester), levodopa (transporter), sulfasalazine (gut azoreductase), acyclovir (viral TK), omeprazole (acid), cyclophosphamide (hepatic oxidation), codeine (3-O-methyl).Pharmacokinetics $$C = C_0e^{-kt}, \quad t_{1/2} = \frac{0.693}{k}, \quad V_d = \frac{D}{C_0}, \quad \mathrm{CL} = kV_d, \quad \mathrm{AUC} = \frac{FD}{\mathrm{CL}}$$$$F = \frac{\mathrm{AUC_{oral}}/D_{\text{oral}}}{\mathrm{AUC_{iv}}/D_{\text{iv}}}, \qquad \text{loading dose} = V_dC_{\text{target}}, \qquad \text{infusion rate} = \mathrm{CL}\,C_{\text{target}}$$
Steady state after 4–5 half-lives , independent of dose; 90% needs 3.32 half-lives. Worked anchor: \( t_{1/2} = 4.0 \) h, \( V_d = 35 \) L → \( k = 0.173 \) h⁻¹, CL = 6.07 L h⁻¹; 350 mg oral at \( F = 0.75 \) → AUC = 43.3 mg h L⁻¹. Saturated (Michaelis–Menten) elimination: first order below \( K_M \), zero order above; half-life no longer constant. ⚠ Trap · Traps
Conjugation called phase I; metabolism assumed always to detoxify; induction and inhibition swapped; \( t_{1/2} \) used in place of \( k \) in \( \mathrm{CL} = kV_d \); a larger dose expected to reach steady state sooner; \( V_d \) treated as a real volume.
Drug classes at a glance Class Target Penicillins, cephalosporins transpeptidase (PBP); clavulanate inhibits β-lactamase Vancomycin D-Ala-D-Ala terminus (substrate, not enzyme) Aminoglycosides, tetracyclines 30S Macrolides, chloramphenicol, oxazolidinones 50S Fluoroquinolones DNA gyrase, topoisomerase IV Sulfonamides dihydropteroate synthase (PABA antimetabolite) Trimethoprim / methotrexate bacterial / human dihydrofolate reductase 5-Fluorouracil (as FdUMP) thymidylate synthase (suicide) Acyclovir, zidovudine viral polymerase / RT — chain termination HIV protease inhibitors aspartyl protease (transition-state isostere) Azoles / polyenes 14α-demethylase (haem Fe) / ergosterol Nitrogen mustards, cisplatin DNA alkylation / cross-linking Vinca alkaloids / taxanes tubulin: destabilise / stabilise Aspirin / other NSAIDs / coxibs COX: irreversible acetylation / reversible / COX-2 pocket Opioids opioid receptors; N-substituent sets agonist vs antagonist β-Blockers β-adrenoceptors (aryloxypropanolamine; \( S \) more active) ACE inhibitors zinc peptidase (thiol or carboxylate zinc-binding group) Dihydropyridines L-type Ca\(^{2+}\) channel (Hantzsch-type 1,4-DHP) Statins HMG-CoA reductase (intermediate mimic) Proton-pump inhibitors H\(^+\)/K\(^+\)-ATPase (acid-activated sulfenamide) Benzodiazepines GABA\(_A\) positive allosteric modulation Local anaesthetics voltage-gated Na\(^+\) channels
⚠ Trap · Traps
Every sulfonamide-containing drug called an antibacterial; clavulanate called the antibiotic; vinca and taxane mechanisms merged; trimethoprim and methotrexate interchanged; the prodrug forgotten (cyclophosphamide, enalapril, acyclovir, levodopa, omeprazole, codeine, sulfasalazine).
Exam pattern for this chapter Per the NTA information bulletin for the December 2026 cycle, Chemical Sciences Part B gives 40 questions (attempt 35, +2/−0.5, maximum 70) and Part C gives 60 questions (attempt 25, +4/−1, maximum 100), in one 3-hour, 200-mark paper. Only the first permitted number of answered questions in a part is evaluated.
Last-minute checklist Where to go next